10-QPeriod: Q1 FY2025

DEXCOM INC Quarterly Report for Q1 Ended Mar 31, 2025

Filed May 1, 2025For Securities:DXCM

Summary

DexCom, Inc. (DXCM) reported its first quarter 2025 financial results, showcasing continued revenue growth driven by increased sensor sales volume and a growing global customer base. While revenue saw a healthy 12% year-over-year increase to $1.04 billion, the company experienced a notable decrease in net income to $105.4 million from $146.4 million in the prior year. This decline was primarily attributed to a significant increase in income tax expense, partly due to shortfalls in share-based compensation, and increased cost of sales which compressed gross profit margins. The company ended the quarter with a strong liquidity position, holding $2.70 billion in cash, cash equivalents, and marketable securities. Management highlighted strategic investments in R&D and product development, including the recent FDA clearance of the Dexcom G7 15 Day CGM System and the launch of the Stelo biosensor for prediabetes and Type 2 diabetes. Despite operational efficiencies in selling, general, and administrative expenses, driven by lower legal costs, investors should monitor the impact of increased cost of goods sold and rising tax expenses on future profitability.

Financial Highlights

50 data points
Beta

Revenue

$1.04B

56.9% Gross Margin

Net Income

$105.40M

10.2% Net Margin

EPS (Diluted)

$0.27

Total Assets

$6.75B

Cash & Equivalents

$904.90M

Free Cash Flow

$96.80M

Financial Statements
Beta
Revenue$1.04B
Cost of Revenue$447.00M
Gross Profit$589.00M
R&D Expenses$145.20M
SG&A Expenses$310.10M
Operating Expenses$455.30M
Operating Income$133.70M
Interest Expense$3.70M
Net Income$105.40M
EPS (Basic)$0.27
EPS (Diluted)$0.27
Shares Outstanding (Basic)391.10M
Shares Outstanding (Diluted)407.50M

Key Highlights

  • 1Revenue increased by 12% year-over-year to $1.04 billion, primarily driven by higher sensor sales volume and customer growth.
  • 2Net income decreased by 28% to $105.4 million, largely due to a significant increase in income tax expense.
  • 3Gross profit margin contracted to 56.9% from 61.0% in the prior year, impacted by inefficiencies in supply availability, production yield, and product/channel mix.
  • 4Selling, general, and administrative expenses decreased by 3% due to lower legal expenses related to a settled patent infringement lawsuit.
  • 5The company maintained a strong liquidity position with $2.70 billion in cash, cash equivalents, and short-term marketable securities.
  • 6Significant investments in research and development continue, supporting new product development and future growth initiatives.
  • 7DexCom received FDA clearance for the G7 15 Day CGM System and launched the Stelo biosensor, expanding its market reach.

Frequently Asked Questions

Revenue growth of 12% to $1.04 billion was primarily driven by increased sales volume of disposable sensors due to the continued growth of Dexcom's worldwide customer base, adding approximately 500,000-600,000 net customers in 2024 (excluding Stelo customers).

Net income decreased by 28% to $105.4 million primarily due to a significant increase in income tax expense for the quarter, which was impacted by shortfalls recognized for employee share-based compensation, net of disallowed executive compensation. Additionally, cost of sales increased at a higher rate than revenue, compressing gross profit margins.

DexCom ended the first quarter of 2025 with a strong liquidity position, reporting $2.70 billion in cash, cash equivalents, and short-term marketable securities.

Yes, DexCom received an FDA warning letter in March 2025 citing deficiencies in manufacturing processes and the quality management system. While this did not restrict current product sales or manufacturing, the company is actively responding and must resolve these issues to the FDA's satisfaction to avoid potential further regulatory actions.